|
|
ASH 2011: Dr Terragna - A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
Carolina Terragna, PhD
Seràgnoli Institute of Hematology
Bologna, Italy
|
|
|
12.07.11 |
To view the video full screen, click on the small
 button next to the volume control in the
lower right hand corner.
|
 related articles
|
|
print